C-peptid (Swedish Wikipedia)

Analysis of information sources in references of the Wikipedia article "C-peptid" in Swedish language version.

refsWebsite

Global rank Swedish rank

16doi.org

2^nd place

14^th place

16nih.gov

4^th place

17^th place

3springer.com

274^th place

271^st place

1xconomy.com

low place

1fiercebiotech.com

low place

doi.org

dx.doi.org

”Insulin biosynthesis: evidence for a precursor”. Science 157 (3789): sid. 697–700. August 1967. doi:10.1126/science.157.3789.697. PMID 4291105.
”Intracellular signalling by C-peptide”. Experimental Diabetes Research 2008: sid. 635158. 2008. doi:10.1155/2008/635158. PMID 18382618.
”C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat”. Diabetologia 44 (7): sid. 889–97. July 2001. doi:10.1007/s001250100570. PMID 11508275.
”Effects of C-peptide on glomerular and renal size and renal function in diabetic rats”. Kidney International 60 (4): sid. 1258–65. October 2001. doi:10.1046/j.1523-1755.2001.00964.x. PMID 11576340.
”C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats”. Nephrology, Dialysis, Transplantation 20 (3): sid. 532–8. March 2005. doi:10.1093/ndt/gfh683. PMID 15665028.
”Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption”. American Journal of Physiology. Renal Physiology 297 (5): sid. F1265-72. November 2009. doi:10.1152/ajprenal.00228.2009. PMID 19741019.
”C-Peptide: the missing link in diabetic nephropathy?”. The Review of Diabetic Studies 6 (3): sid. 203–10. 2009. doi:10.1900/RDS.2009.6.203. PMID 20039009.
”Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway”. Diabetologia 51 (8): sid. 1534–43. August 2008. doi:10.1007/s00125-008-1032-x. PMID 18493738.
”Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein”. Diabetologia 53 (8): sid. 1761–71. August 2010. doi:10.1007/s00125-010-1736-6. PMID 20461358.
”Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)”. Cardiovascular Diabetology 20. 2021. doi:10.1186/s12933-021-01418-z. PMID 34879878.
”The clinical utility of C-peptide measurement in the care of patients with diabetes”. Diabetic Medicine 30 (7): sid. 803–17. July 2013. doi:10.1111/dme.12159. PMID 23413806.
”Assays for insulin, proinsulin(s) and C-peptide”. Annals of Clinical Biochemistry 36 ( Pt 5) (5): sid. 541–64. September 1999. doi:10.1177/000456329903600501. PMID 10505204.
”Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration”. The Journal of Clinical Endocrinology and Metabolism 67 (5): sid. 1094–9. November 1988. doi:10.1210/jcem-67-5-1094. PMID 3053748.
R, Chandini; Udayabhaskaran V; Binoy J Paul; K.P Ramamoorthy (July 2013). ”A study of non-obese diabetes mellitus in adults in a tertiary care hospital in Kerala, India”. International Journal of Diabetes in Developing Countries 33 (2): sid. 83–85. doi:10.1007/s13410-013-0113-7.
”C-peptide and diabetic kidney disease”. Journal of Internal Medicine 281 (1): sid. 41–51. January 2017. doi:10.1111/joim.12548. PMID 27640884.
”C-peptide as a Therapy for Kidney Disease: A Systematic Review and Meta-Analysis”. PLOS ONE 10 (5): sid. e0127439. 2015. doi:10.1371/journal.pone.0127439. PMID 25993479.

fiercebiotech.com

Garde, Damian (February 24, 2015). ”Cebix hangs it up after raising $50M for diabetes drug”. FierceBiotech. http://www.fiercebiotech.com/r-d/cebix-hangs-it-up-after-raising-50m-for-diabetes-drug.

nih.gov

ncbi.nlm.nih.gov

”Insulin biosynthesis: evidence for a precursor”. Science 157 (3789): sid. 697–700. August 1967. doi:10.1126/science.157.3789.697. PMID 4291105.
”Intracellular signalling by C-peptide”. Experimental Diabetes Research 2008: sid. 635158. 2008. doi:10.1155/2008/635158. PMID 18382618.
”C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat”. Diabetologia 44 (7): sid. 889–97. July 2001. doi:10.1007/s001250100570. PMID 11508275.
”Effects of C-peptide on glomerular and renal size and renal function in diabetic rats”. Kidney International 60 (4): sid. 1258–65. October 2001. doi:10.1046/j.1523-1755.2001.00964.x. PMID 11576340.
”C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats”. Nephrology, Dialysis, Transplantation 20 (3): sid. 532–8. March 2005. doi:10.1093/ndt/gfh683. PMID 15665028.
”Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption”. American Journal of Physiology. Renal Physiology 297 (5): sid. F1265-72. November 2009. doi:10.1152/ajprenal.00228.2009. PMID 19741019.
”C-Peptide: the missing link in diabetic nephropathy?”. The Review of Diabetic Studies 6 (3): sid. 203–10. 2009. doi:10.1900/RDS.2009.6.203. PMID 20039009.
”Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway”. Diabetologia 51 (8): sid. 1534–43. August 2008. doi:10.1007/s00125-008-1032-x. PMID 18493738.
”Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein”. Diabetologia 53 (8): sid. 1761–71. August 2010. doi:10.1007/s00125-010-1736-6. PMID 20461358.
”Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)”. Cardiovascular Diabetology 20. 2021. doi:10.1186/s12933-021-01418-z. PMID 34879878.
”The clinical utility of C-peptide measurement in the care of patients with diabetes”. Diabetic Medicine 30 (7): sid. 803–17. July 2013. doi:10.1111/dme.12159. PMID 23413806.
”Assays for insulin, proinsulin(s) and C-peptide”. Annals of Clinical Biochemistry 36 ( Pt 5) (5): sid. 541–64. September 1999. doi:10.1177/000456329903600501. PMID 10505204.
”Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration”. The Journal of Clinical Endocrinology and Metabolism 67 (5): sid. 1094–9. November 1988. doi:10.1210/jcem-67-5-1094. PMID 3053748.
”C-peptide and diabetic kidney disease”. Journal of Internal Medicine 281 (1): sid. 41–51. January 2017. doi:10.1111/joim.12548. PMID 27640884.
”C-peptide as a Therapy for Kidney Disease: A Systematic Review and Meta-Analysis”. PLOS ONE 10 (5): sid. e0127439. 2015. doi:10.1371/journal.pone.0127439. PMID 25993479.

pubchem.ncbi.nlm.nih.gov

C-Peptide - Compound Summary, PubChem.

springer.com

adisinsight.springer.com

”C-peptide - Creative Peptides -”. C-peptide - Creative Peptides -. AdisInsight. http://adisinsight.springer.com/drugs/800010430.
”C-peptide - Eli Lilly”. C-peptide - Eli Lilly. AdisInsight. http://adisinsight.springer.com/drugs/800005551.
”C-peptide long-acting - Cebix”. adisinsight.springer.com. AdisInsight. http://adisinsight.springer.com/drugs/800034107.

xconomy.com

Bigelow, Bruce V. (23 February 2015). ”Cebix Shuts Down Following Mid-Stage Trial of C-Peptide Drug”. Xconomy. http://www.xconomy.com/san-diego/2015/02/23/cebix-shuts-down-following-mid-stage-trial-of-c-peptide-drug/#.